Centocor Novel Psoriasis Biologic On Track Following Positive Phase III

Johnson & Johnson subsidiary reports positive results of a Phase III study evaluating the monoclonal antibody targeting interleukin 12 and interleukin 23.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet